Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, the efficacy of mouse p16 peptide administration in a mouse lung metastasis model for BT and also the toxicity of peptides by cardiac peptide injection were evaluated.
|
30655885 |
2019 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
|
30446453 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Significantly higher rates of TP53 and CDKN2A mutation rates (p = 0.005 and 0.035, respectively) were encountered in muscle-invasive bladder tumors compared with those of pT1 stage.
|
31028363 |
2019 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations in CDKN2A and the FGFR3 genes on bladder cancer diagnosis: a systematic review and meta-analysis.
|
31028457 |
2019 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer.
|
30149755 |
2018 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, P16 gene amplification accompanied protein high-expression has shorter overall survival compared with the overall patients (P = .023), and P16 gene loss accompanied loss of protein also had the tendency to predict bad prognosis (P = .067).Studies show that the genetic status of P16 has a close relation with the stages of bladder cancer.
|
29642177 |
2018 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, we provided evidence that Jarid2 via modulation of p16 is a putative novel therapeutic target for treating malignant bladder cancer.
|
28445934 |
2017 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We identified a miR-877-3p binding site on the promoter site of tumor suppressor gene p16 which alters frequently in bladder cancer.
|
27429046 |
2016 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, DE-miRNAs in bladder cancer tissue samples and DE-targeted genes, such as miR-106b and CDKN2A, which were identified in the present study, may provide the basis for targeted therapy for breast cancer and enhance understanding of its pathogenesis.
|
25955758 |
2015 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Detection of human papillomavirus infection and p16 immunohistochemistry expression in bladder cancer with squamous differentiation.
|
24675970 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ASSET analyses identified four SNPs significantly associated with multiple cancers: rs3731239 (CDKN2A intronic) with ESCC, GC and BC (P = 3.96 × 10(-) (4)); rs10811474 (3' of IFNW1) with RCC and BrC (P = 0.001); rs12683422 (LINGO2 intronic) with RCC and BC (P = 5.93 × 10(-) (4)) and rs10511729 (3' of ELAVL2) with LC and BrC (P = 8.63 × 10(-) (4)).
|
25239644 |
2014 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, the systemic peptide delivery of p16 restores the hypophosphorylation of pRb and may be a useful tool for the treatment of bladder tumors.
|
23292502 |
2013 |
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
p14 hypermethylation could be involved in early stage of bladder carcinogenesis, and p14 hypermethylation in pathologically normal urothelium samples should be considered a predictor of bladder cancer recurrence.
|
20800513 |
2012 |
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer.
|
23083854 |
2012 |
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
We analyzed the methylation of P16INK4a and P14ARF in 80 tissues and matched blood samples of patients suffering from bladder cancer and 80 blood samples of cancer-free individuals by MS-PCR.
|
20683150 |
2010 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
LHGDN |
Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers.
|
18334837 |
2008 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we show that low-level expression of a constitutively active Ha-ras in mouse urothelium induces simple urothelial hyperplasia that is resistant to progression to full-fledged bladder tumors even in the absence of Ink4a/Arf.
|
17256055 |
2007 |
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the prognostic role of p16 expression and loss of heterozygosity (LOH) on chromosome 9p21 in patients affected by low-grade (G1-G2) urothelial bladder cancer.
|
17612565 |
2007 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.
|
15987713 |
2006 |
Bladder Neoplasm
|
0.600 |
Therapeutic
|
disease |
CTD_human |
We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.
|
15987713 |
2006 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Using methylation-specific PCR (MSP), we examined the methylation status of p16(INK4a) and p14(ARF) in 64 samples from 45 bladder cancer patients (34 males, 11 females).
|
16316628 |
2006 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We, therefore, examined, in a population-based study of human bladder cancer (n = 351), the relationship between epigenetic silencing of the tumor-suppressor genes, p16(INK4A), RASSF1A, PRSS3, and the four SFRP genes and exposure to both tobacco and arsenic in bladder cancer.
|
17119258 |
2006 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
To determine p53 and p16 status as molecular markers of bladder cancer, in histologically proven benign bladder biopsies, obtained from lesions suspect for malignancy as judged by fluorescence cystoscopy.
|
17021825 |
2006 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
CTD_human |
We, therefore, examined, in a population-based study of human bladder cancer, the relationship between epigenetic silencing of three tumor suppressor genes, p16(INK4A), RASSF1A and PRSS3, and exposure to both tobacco and arsenic in bladder cancer.
|
15987713 |
2006 |
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
LHGDN |
Using methylation-specific PCR (MSP), we examined the methylation status of p16(INK4a) and p14(ARF) in 64 samples from 45 bladder cancer patients (34 males, 11 females).
|
16316628 |
2006 |